相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Randomized, Double-Blind, Phase 2 Trial of Platinum Therapy Plus Etoposide With or Without Concurrent Vandetanib (ZD6474) in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer: Hoosier Cancer Research Network LUN06-113
Rachel E. Sanborn et al.
CANCER (2017)
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Marcello Tiseo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
Michael J. Seckl et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial
Lauren Averett Byers et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn et al.
LANCET ONCOLOGY (2017)
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
Toshiaki Takahashi et al.
LANCET ONCOLOGY (2017)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial
Ben J. Slotman et al.
LUNG CANCER (2017)
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor
Kentaro Inamura et al.
CANCER MEDICINE (2017)
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
Mark A. Socinski et al.
CLINICAL LUNG CANCER (2017)
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
Bonnie Glisson et al.
CLINICAL LUNG CANCER (2017)
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group
F. Koinis et al.
BRITISH JOURNAL OF CANCER (2017)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu et al.
CANCER CELL (2017)
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)
Chandra P. Belani et al.
CANCER (2016)
Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
Dimitrios T. Trafalis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
SLFN11 is a biomarker of sensitivity to PARP inhibition and chemotherapy in small cell lung cancer (SCLC)
C. Allison Stewart et al.
CANCER RESEARCH (2016)
No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials
Giandomenico Roviello et al.
CLINICAL LUNG CANCER (2016)
Optimal drugs for second-line treatment of patients with small-cell lung cancer
Antonio Rossi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
Koichi Goto et al.
LANCET ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
A phase II study of nintedanib in patients with relapsed small cell lung cancer
Ji-Youn Han et al.
LUNG CANCER (2016)
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
Nobuyuki Horita et al.
SCIENTIFIC REPORTS (2016)
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial
J. -L. Pujol et al.
ANNALS OF ONCOLOGY (2015)
Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer
Oleg Gladkov et al.
ANTI-CANCER DRUGS (2015)
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis
Giovenzio Genestreti et al.
CLINICAL LUNG CANCER (2015)
PD-L1 expression in small cell lung cancer
Takefumi Komiya et al.
EUROPEAN JOURNAL OF CANCER (2015)
PD-L1 expression in small cell neuroendocrine carcinomas
Anne M. Schultheis et al.
EUROPEAN JOURNAL OF CANCER (2015)
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)
Neal E. Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
Hidenobu Ishii et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer
Shun Lu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Radiotherapy for extensive stage small-cell lung cancer Reply
Ben J. Slotman et al.
LANCET (2015)
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
Ben J. Slotman et al.
LANCET (2015)
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
Bohuslav Melichar et al.
LANCET ONCOLOGY (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials
Andrea Ardizzoni et al.
EUROPEAN JOURNAL OF CANCER (2014)
Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer
Neelesh Sharma et al.
INVESTIGATIONAL NEW DRUGS (2014)
Aurora Kinase Inhibition As an Anticancer Strategy
John F. Hilton et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer
Jeffrey W. Allen et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Joachim von Pawel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer
Philip E. Lammers et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase
Marjorie G. Zauderer et al.
LUNG CANCER (2014)
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer
Corey J. Langer et al.
LUNG CANCER (2014)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Frueh et al.
ANNALS OF ONCOLOGY (2013)
Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
David R. Spigel et al.
CLINICAL LUNG CANCER (2013)
A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer
Ji-Youn Han et al.
LUNG CANCER (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Duration of Chemotherapy for Small Cell Lung Cancer: A Meta-Analysis
Hang Zhou et al.
PLOS ONE (2013)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group
Giannis Mountzios et al.
LUNG CANCER (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer
Zheng-tao Zhou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
Robert Jotte et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Small-cell lung cancer
Jan P. van Meerbeeck et al.
LANCET (2011)
Treatment of Small-Cell Lung Cancer in Elderly Patients
Athanasios G. Pallis et al.
CANCER (2010)
Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group
Shadia Jalal et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis
Antonio Rossi et al.
LUNG CANCER (2010)
Evaluation of the Use of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Shilpen Patel et al.
CANCER (2009)
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Siow Ming Lee et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial
Cecile Le Pechoux et al.
LANCET ONCOLOGY (2009)
Poly(ADP-ribose) polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks
Bethany C. Woodhouse et al.
DNA REPAIR (2008)
Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The International Association for the study of Lung Cancer - Lung Cancer staging project: Proposals regarding the clinical staging of small cell Lung Cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for Lung Cancer
Frances A. Shepherd et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada clinical trials group study BR. 20
Andrew M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy:: An intergroup study FNCLCC cleo04-IFCT 00-01
Jean Louis Pujol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Small cell lung cancer: Have we made any progress over the last 25 years?
Brian E. Lally et al.
ONCOLOGIST (2007)
Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20
A. M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R. Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)
R Tsuchiya et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2005)
PARP-1, a determinant of cell survival in response to DNA damage
WJ Bouchard et al.
EXPERIMENTAL HEMATOLOGY (2003)
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up
S Sundstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patinets with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organisation for the Research and Treatment of Cancer
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Small cell lung carcinoma (SCLC) - A clinicopathologic study of 100 cases with surgical specimens
SA Nicholson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104
M Takada et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
W Noda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The treatment of limited small cell lung cancer: a report of the progress made and future prospects
AT Turrisi et al.
EUROPEAN JOURNAL OF CANCER (2002)
分享论文
